Stock MVR0 MEDIVIR AB
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Medivir AB Deutsche Boerse AG

Equities

MVR0

SE0020181014

Delayed Deutsche Boerse AG
Other stock markets
 15:50:03 2024-07-16 EDT 		5-day change 1st Jan Change
0.228 EUR +3.17% Intraday chart for Medivir AB -1.30% +4.20%
06-27 Medivir AB Presents Positive New Data from Its Ongoing Phase Ib / IIa Study of Fostroxacitabine Bralpamide + Lenvima® in Advanced Hepatocellular Carcinoma CI
06-20 Certain Shares of Medivir AB are subject to a Lock-Up Agreement Ending on 20-JUN-2024. CI

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Number of shares and votes in Medivir AB on 28 June 2024
AQ
BioStock: Medivir presents promising results in difficult-to-treat patient population
AQ
Medivir : Presentation
PU
Fostrox + Lenvima® holds promise of greatly improved outcomes for advanced liver cancer patients, reveals new data from Medivir at ESMO GI
AQ
Medivir selects global CRO partner for upcoming phase 2b study in HCC with fostrox + Lenvima and initiates study feasibility
AQ
Issue, repurchase and reclassification of shares of series C and transfer of ordinary shares under LTIP 2024
AQ
Medivir to present at Redeye Growth Day
AQ
Medivir : acute;s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program
PU
Medivir's licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program
AQ
Resolutions at the Annual General Meeting in Medivir on 7 May 2024
AQ
BioStock: Double thumbs up for Medivir from the FDA
AQ
MEDIVIR AB - INTERIM REPORT JANUARY - MARCH 2024
AQ
Medivir brings the Q1 webcast forward to 10 a.m. on April 30
AQ
Medivir to present data for the combination of fostrox + Lenvima in HCC at ESMO GI
AQ
BioStock: Medivir optimizes study design after meeting FDA
AQ
Medivir : FDA grants Medivir´s MIV-711 Rare Pediatric Disease Designation and Orphan Drug Designation for the treatment of Legg-Calvé-Perthes Disease
PU
FDA grants Medivir's MIV-711 Rare Pediatric Disease Designation and Orphan Drug Designation for the treatment of Legg-Calvé-Perthes Disease
AQ
Medivir provides update from supportive Type C meeting with the FDA; preparations for enhanced phase 2b in HCC with fostrox + Lenvima continue
AQ
BioStock: Medivir's partner makes clinical progress in veterinary project
AQ
Medivir : The Board of Directors statement under Chapter 19 Section 22 of the Swedish Companies Act
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MVIR B Stock
  4. MVR0 Stock
  5. News Medivir AB
  6. Press Releases